Wave Life Sciences Research Day - WAVE LIFE SCIENCES INC

Explicit Guidance:

• Filing of a Clinical Trial Application (CTA) for WVE-008 in the fourth quarter of 2026.
• Initiation of a maintenance trial for WVE-007 (inhibin) in 2026.
• Sharing of data from the 600 mg cohort of the Phase I ENLIGHT trial for WVE-007 in 2026.
• Sharing of data from the 600 mg cohort of the Phase I RESTORATION II trial for WVE-006 in 2026.

Business-Segment Outlook:

• WVE-008 (PNPLA3-I148M): Advancing a galactose-conjugated RNA editing candidate for homozygous PNPLA3-I148M liver disease (MASLD, MASH, alcohol-associated liver disease, cirrhosis, HCC); aiming to edit at least 50% of transcripts to shift risk profile from homozygous to heterozygous. Preclinical data shows >60% editing in hepatic stellate cells and >85% editing in human hepatocytes.
• WVE-007 (Inhibin): Phase IIa clinical trial ongoing for obesity/weight loss with SPINA design; demonstrating sustained suppression for 7+ months after a single dose, enabling once- or twice-yearly dosing. Preclinical data indicates superior weight loss preservation of lean mass compared to incretins and potential for add-on synergy (2x weight loss vs. incretin alone) and maintenance (preventing regain post-treatment).
• WVE-006 (AATD): Validated RNA editing platform; clinical data shows durable editing, increased M protein, decreased Z protein, and restoration of inflammatory response.
• Platform Innovations: Launching SPINA design siRNAs for extrahepatic delivery (adipose, kidney, dual liver/adipose) using PN conjugates; developing bifunctional constructs capable of simultaneous silencing/editing/upregulating two targets (e.g., LPA/PCSK9, PCSK9/LDLR) to enhance potency and durability.
• Manufacturing: Establishing an oligonucleotide center of excellence to accelerate discovery and scalable, cost-effective manufacturing of stereopure oligonucleotides.

Market and Competitive Outlook:

• Addressable Population: >9 million homozygous I148M individuals in the U.S. and Europe; commercial genetic testing (e.g., 23andMe) available to identify carriers.
• Competitive Differentiation: RNA editing (WVE-008) expected to be superior to PNPLA3 silencing (siRNA), which shows clinical liabilities (worsened steatosis/inflammation in some models) and limited efficacy in MASH resolution compared to GLP-1s.
• Targeting Strategy: Moving from broad MASH markets to precision medicine by enriching trials for homozygous carriers to accelerate proof-of-concept and maximize therapeutic impact on fibrosis and survival.

Macro / Industry Outlook:

• Disease Progression: PNPLA3-I148M mutation is the strongest genetic risk factor for liver disease progression, fibrosis, and hepatocellular carcinoma; homozygous carriers have a 9-fold higher risk of liver-related death.
• Market Gap: No approved therapies directly target the PNPLA3 driver; current GLP-1 therapies (e.g., tirzepatide) show weaker MASH resolution in mutation carriers.
• Regulatory Path: Aiming for accelerated approval pathways using surrogate endpoints (steatosis, fibrosis biomarkers) with a potential confirmatory trial following, estimating a 1–1.5 year timeline for proof of concept in fibrosis patients.

Strategic Initiatives:

• Clinical Trial Execution: Leveraging pre-existing genetic databases to pre-identify and enroll homozygous I148M carriers, expediting trial initiation and de-risking mechanism validation.
• Bifunctional Modality Expansion: Continuing to develop dual-target oligonucleotides (silencing/editing/upregulating) to address complex indications like hypercholesterolemia (silencing PCSK9 + upregulating LDLR) and cardiovascular risk.
• Partnerships: Continuing to drive optionality across the portfolio; validating platform via GSK partner (TTR siRNA) and assessing M&A/partnering opportunities for assets where external capital/development speed is optimal.

Risks and Headwinds to Outlook:

• Biological Balance: "Goldilocks" risk in PNPLA3 editing; over-editing (loss of function) could impair triglyceride mobilization and worsen steatosis, requiring precise ~50-85% editing levels rather than complete knockdown.
• Trial Complexity: Long timelines for liver disease outcomes (cirrhosis, mortality); need to differentiate mechanism from standard-of-care GLP-1s.
• Regulatory/Commercial: Dependence on genetic testing adoption for patient identification; potential skepticism regarding functional activity of edited protein (Valine vs. Isoleucine substitution), though preclinical data supports functional restoration.

Management Tone on the Future:

• High Confidence: Management expresses "strong conviction" in the SPINA platform's potency and durability, citing "unprecedented" improvements in potency and duration versus industry benchmarks.
• Optimistic on Precision: View on PNPLA3 is that correcting the mutation offers a unique opportunity to reverse disease activity (fat, inflammation, fibrosis) rather than just prevent progression, positioning WVE-008 as a first-in-class disease-modifying treatment.
• Aggressive Pacing: Emphasis on "speed and efficiency" in clinical execution, leveraging genotype-enriched populations to rapidly de-risk the WVE-008 program.

Miscellaneous:

• SPINA Chemistry: Stereochemically pure designs demonstrate >10-fold improvement in AGO2 loading and >10-fold improvement in potency/durability vs. reference siRNAs, applicable across targets (TTR, PCSK9, Inhibin) without sequence-specific re-optimization.
• Delivery Expansion: PN conjugates successfully tuned for silencing in extrahepatic tissues (adipose up to 90% knockdown, kidney proximal/distal tubules), enabling dual-tissue targeting (liver + adipose) for cardiometabolic indications.